<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03045614</url>
  </required_header>
  <id_info>
    <org_study_id>AZ 238/16</org_study_id>
    <nct_id>NCT03045614</nct_id>
  </id_info>
  <brief_title>Kidney Disease and Pulmonary Hypertension</brief_title>
  <official_title>Prevalence and Predictors of Kidney Disease, and Long-Term Renal Outcome in Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the prevalence of kidney disease, hemodynamic predictors and long-term renal
      outcome in patients with invasively diagnosed pulmonary hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to determine the prevalence of kidney disease, hemodynamic predictors and
      long-term renal outcome of in-hospital patients with invasively diagnosed pulmonary
      hypertension at the Department of Pulmonology, University Hospital Giessen and Marburg,
      Giessen, Germany between 1999 and 2016.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Actual">August 28, 2018</completion_date>
  <primary_completion_date type="Actual">August 27, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in estimated glomerular filtration rate (GFR) in each class of pulmonary hypertension during follow-up period</measure>
    <time_frame>3 years follow-up</time_frame>
    <description>Estimated GFR (Chronic Kidney Disease Epidemiology Collaboration) will be used over follow-up period to determine changes in renal function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of renal function on deterioration of pulmonary hypertension during follow-up period</measure>
    <time_frame>3 years follow-up</time_frame>
    <description>Changes in estimated GFR (Chronic Kidney Disease Epidemiology Collaboration) over follow-up period will be correlated with clinical worsening of pulmonary hypertension (as determined by echocardiography, 6-minute-walk, New York Heart Association classification, b-type natriuretic peptide)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of pulmonary hypertension-related morbidity on renal function decline</measure>
    <time_frame>3 years follow-up</time_frame>
    <description>Severity of pulmonary hypertension (progress pulmonary hypertension, unscheduled hospitalization due to worsening of pulmonary hypertension, mortality) will be correlated with changes in renal function (as determined by estimated GFR [Chronic Kidney Disease Epidemiology Collaboration])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of proteinuria in pulmonary hypertension</measure>
    <time_frame>At baseline</time_frame>
    <description>24 hours urine collection at baseline will be assessed to predict progress of pulmonary hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of pulmonary hypertension-specific therapy on renal function decline</measure>
    <time_frame>3 years follow-up</time_frame>
    <description>Estimated GFR (Chronic Kidney Disease Epidemiology Collaboration) over follow-up period will be assessed to show association of pulmonary hypertension-specific therapy on renal function</description>
  </secondary_outcome>
  <enrollment type="Actual">824</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Collection of only residual material (blood, urine) for Deutsche Zentrum f√ºr Lungenforschung
      Biobank.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with invasively diagnosed pulmonary hypertension between March 1999 and
        December 2016 at reference center for pulmonary hypertension, University Hospital Giessen,
        Germany.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  older than 18 years

          -  subjects with invasively diagnosed pulmonary hypertension at rest and available renal
             function and spot urine data at day of right heart catheterization between March 1999
             and December 2016 at the Department of Pulmonology, University Hospital Giessen and
             Marburg, Giessen, Germany

        Exclusion Criteria:

          -  subjects with estimated GFR &lt;15ml/min/1.73m2 or prior dialysis

          -  pre-existing acute kidney injury

          -  non-end stage renal disease with extracorporeal or peritoneal ultrafiltration due to
             diuretic-resistant fluid overload

          -  primary kidney disease requiring active immunosuppression

          -  autosomal dominant polycystic kidney disease

          -  if subjects are pregnant

          -  if subjects are recipients of solid-organ transplants

          -  subjects with pulmonary hypertension with unclear/multifactorial mechanisms (WHO group
             5 pulmonary hypertension)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Werner Seeger, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Clinic Giessen and Marburg, Campus Giessen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Clinic Giessen and Marburg - Campus Giessen</name>
      <address>
        <city>Giessen</city>
        <state>Hessen</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Navaneethan SD, Wehbe E, Heresi GA, Gaur V, Minai OA, Arrigain S, Nally JV Jr, Schold JD, Rahman M, Dweik RA. Presence and outcomes of kidney disease in patients with pulmonary hypertension. Clin J Am Soc Nephrol. 2014 May;9(5):855-63. doi: 10.2215/CJN.10191013. Epub 2014 Feb 27.</citation>
    <PMID>24578332</PMID>
  </results_reference>
  <results_reference>
    <citation>Husain-Syed F, Slutsky AS, Ronco C. Lung-Kidney Cross-Talk in the Critically Ill Patient. Am J Respir Crit Care Med. 2016 Aug 15;194(4):402-14. doi: 10.1164/rccm.201602-0420CP. Review.</citation>
    <PMID>27337068</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 4, 2017</study_first_submitted>
  <study_first_submitted_qc>February 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2017</study_first_posted>
  <last_update_submitted>November 17, 2019</last_update_submitted>
  <last_update_submitted_qc>November 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Giessen</investigator_affiliation>
    <investigator_full_name>Faeq Husain</investigator_full_name>
    <investigator_title>Senior Physician Nephrology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data that support the findings of this study are available from the corresponding author upon reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Unlimited</ipd_time_frame>
    <ipd_access_criteria>The data that support the findings of this study are available from the corresponding author upon reasonable request.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

